News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Slideshows|April 4, 2017

IBIA 2017: Repercussions of TBI

Author(s)Samantha J. Peterson

Research presented at IBIA 2017 looked at risk behavior in adolescents, return to work, and maladaptive emotion regulation following TBI.

Research from the International Brain Injury Association’s World Congress examined various consequences of TBI. Studies included a possible link between childhood TBI and later risk behavior, completeness of return to work following mild TBI, and associations between TBI, PTSD, and maladaptive emotion regulation.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Evaluating the Impact of Oveporexton in Phase 3 Studies for Narcolepsy Type 1: Elena Koundourakis, PhD

ByElena Koundourakis, PhD,Isabella Ciccone, MPH

July 21st 2026

Using a Machine Learning–Based EHR Model to Enhance Screening for Obstructive Sleep Apnea: Nathanael Hwang

ByNathanael Hwang,Isabella Ciccone, MPH

July 20th 2026

Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose

ByMarco Meglio,Laura Nisenbaum, PhD

July 20th 2026

FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date

July 20th 2026

Building the Foundation for Earlier Alzheimer Disease Diagnosis

ByYogesh Shah, MD, MPH, FAAFP

July 20th 2026

Latest CME

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial

Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline

FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date

Building the Foundation for Earlier Alzheimer Disease Diagnosis

Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose